Original Article
Cost Effectiveness of Replacing Recombinated Interferon α−2b with its Pegylated Form in Combination with Ribavirin for the Therapy of Chronic HCV Infection in Poland
Krzysztof Simon, Andrzej Gładysz, Katarzyna Rotter, Weronika Rymer, Patryk Smoliński, Małgorzata Inglot, Magdalena Władysiuk−Blicharz
453-462